RecruitingNCT06116019

Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)

A Prospective Study on Online Adaptive Radiotherapy (ART) Using the ETHOS Linear Accelerator for Various Tumor Entities and the Feasibility of Integrating Multi-Parametric Patient Data Into the Adaptive Workflow

Sponsor

Charite University, Berlin, Germany

Enrollment

649 participants

Start Date

Oct 11, 2023

Study Type

OBSERVATIONAL

Conditions

Esophageal Cancer Prostate Cancer Head and Neck Cancer NSCLC SCLC Bladder Cancer Rectum Cancer Cervix Cancer Other Carcinoma

Summary

The study focuses on the scientific and clinical evaluation of online adaptive radiotherapy (ART) using the Varian/SHS ETHOS treatment system. In this study, radiation treatment plans are dynamically adjusted on a daily basis over several weeks of therapy to account for anatomical shifts in either the tumour or adjacent normal tissue - a capability that has been difficult to achieve due to technical limitations. With the ETHOS accelerator, such real-time adjustments can be made based on cone beam computed tomography (CBCT). This is a prospective observational study with the primary objective of investigating the feasibility and acceptability of performing ART with ETHOS for different tumour entities. The study will also evaluate the feasibility of integrating multi-parametric data sets into the ART workflow, such as standardised electronic feedback on treatment toxicity from both patients (ePROMS) and physicians (ePRT).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study evaluates a new, more advanced form of radiation therapy called online adaptive radiotherapy, delivered by a system called ETHOS. Unlike standard radiation, this approach adjusts the treatment plan in real time at each session based on how the tumor and surrounding organs have shifted — potentially reducing damage to healthy tissue. **You may be eligible if:** - You are 18 or older - You have any type of tumor for which radiation therapy or chemoradiation is recommended - You are able to give informed consent **You may NOT be eligible if:** - You are pregnant - You are not able to give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.